Study to investigate safety, tolerability and pharmacokinetics with single and multiple ascending doses of AZD1446
Study identifier:D1950C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Male and Non-fertile Female, young and Elderly Healthy Volunteers, After Oral Multiple Ascending Doses
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD1446, Placebo
Sex
All
Actual Enrollment
80
Study type
Interventional
Age
18 Years - 80 Years
Date
Study Start Date: 01 Apr 2009
Primary Completion Date: 01 Sept 2009
Study Completion Date: 01 Sept 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Part A single and multiple dose and part B fractionated dose | Drug: AZD1446 Solution, oral single and multiple dose |
| Placebo Comparator: 2 | Drug: Placebo Placebo |
Contacts
Investigators
Principal Investigator
Björn Paulsson
AstraZeneca
